In addition, and in lieu of common stock, Assembly sold to a certain existing investor pre-funded warrants to purchase up to an aggregate of 2,424,242 shares of common stock at a purchase price of $16.499 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. Assembly intends to use the net proceeds from the sale of the common stock to fund clinical trials, nonclinical studies, research and development and for general corporate purposes.

Assembly Biosciences, Inc. (NASDAQ:ASMB) shareholders might be concerned after seeing the share price drop 11% in the...

In addition, and in lieu of common stock, Assembly is offering to a certain existing investor pre-funded warrants to purchase up to an aggregate of 2,424,242 shares of common stock at a purchase price of $16.499 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant. The offering is expected to close on or about December 16, 2019, subject to the satisfaction of customary closing conditions. Assembly has granted the underwriters a 30-day option to purchase up to an additional 1,136,363 shares of common stock at the offering price, less the underwriting discounts and commissions.

Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the appointment of Jason Okazaki as Chief Legal and Business Officer. Mr. Okazaki has 20 years of legal and biotechnology industry experience, both as internal counsel and with a leading law firm. “Jason brings extensive legal expertise and a depth of invaluable industry and business experience, and we are excited to have him join the Assembly team,” said John McHutchison, AO, MD, Chief Executive Officer and President.

SOUTH SAN FRANCISCO, Calif., May 26, 2020 -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting.

As of late, it has definitely been a great time to be an investor Assembly Biosciences

-- Advancing the development of three clinical-stage core inhibitor candidates in HBV portfolio ---- Cash position of $249 million projected to fund operations into 2022 ----.

The ePoster includes preclinical data from the Company’s microbiome program in ulcerative colitis (UC) and is also scheduled for publication in the May online supplements to the journals Gastroenterology and GIE: Gastrointestinal Endoscopy. A copy of the ePoster is available on Assembly Biosciences’ website.

-- Expert Virologist and Biologist William Delaney, PhD joins as Chief Scientific Officer, Virology --  -- EVP and CSO of Virology Operations Richard Colonno, PhD to retire --.

The study was led by Qi Huang, PhD, the Company’s Vice President of Virology Discovery, and was conducted in collaboration with Professors Jinlin Hou, Jian Sun, and Bin Zhou of Nanfang Hospital, Southern Medical University in Guangzhou, China. The article is entitled Rapid Turnover of HBV cccDNA Indicated by Monitoring Emergence and Reversion of Signature‐Mutation in Treated Chronic Hepatitis B Patients and is available online with open access.

SOUTH SAN FRANCISCO, Calif., April 30, 2020 -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting.

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 11) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics ...

If you own shares in Assembly Biosciences, Inc. (NASDAQ:ASMB) then it's worth thinking about how it contributes to the...

Assembly Biosciences (ASMB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Assembly Biosciences (ASMB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 1.98% and 27.73%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

The stock options have a ten-year term and vest over four years, with one-fourth vesting on the first anniversary of the date of grant and the remaining three-fourths vesting in approximately equal monthly installments thereafter. The stock options in all cases are subject to the employees’ continued service with Assembly through the applicable vesting dates and to acceleration upon the occurrence of certain events as set forth in the stock option agreements. The stock options were granted outside of Assembly’s stockholder-approved equity incentive plans pursuant to Assembly’s 2020 Inducement Award Plan.

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2020 -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting.

SOUTH SAN FRANCISCO, Calif., March 04, 2020 -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting.

This change is to protect the safety, health and well-being of its stockholders, directors, employees and the public during the COVID-19 pandemic. Stockholders will not be able to attend the Annual Meeting in person at a physical location. Despite the change to a virtual-only meeting, the proxy card or voting instruction form, as applicable, included with previously-distributed proxy materials will not be updated to reflect the change from an in-person meeting to a virtual-only meeting and may be used to vote shares in connection with the Annual Meeting.